Evidence map›Paper›PMID 39281359›Full record

ArticlePaediatrics & child health2024

Gene-based drug therapy for children and youth treated with psychoactive medications.

Ruud H J Verstegen, Iris Cohn, Mark E Feldman, Daniel Gorman, Shinya Ito

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Paediatrics & child health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ruud H J VerstegenCanadian Paediatric Society, Drug Therapy Committee, Ottawa, Ontario, Canada.
Iris CohnCanadian Paediatric Society, Drug Therapy Committee, Ottawa, Ontario, Canada.
Mark E FeldmanCanadian Paediatric Society, Drug Therapy Committee, Ottawa, Ontario, Canada.
Daniel GormanCanadian Paediatric Society, Drug Therapy Committee, Ottawa, Ontario, Canada.
Shinya ItoCanadian Paediatric Society, Drug Therapy Committee, Ottawa, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psychoactive medications are increasingly used to treat children and youth with mental health conditions, but individual variations in response highlight the need for precision medicine. Pharmacogenetic (PGx) testing is a key component of precision medicine. The number of commercial pharmacogenetic testing companies promoting PGx, with the promise of achieving individualized and effective treatment of mental health conditions, has grown exponentially in recent years. Scientific evidence supporting the use of PGx to manage mental health conditions is limited, especially for paediatric populations. This practice point outlines steps guiding the use and interpretation of PGx testing for psychoactive medications in clinical settings, along with key supportive resources. Practice guidelines have been developed for variants in pharmacogenes encoding cytochrome P450 drug-metabolizing enzymes (e.g.,

Indexed as

Child and youth mental healthChild psychiatryPharmacogenetic testingPrecision medicine

Identifiers

PMID39281359
PMCPMC11398941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.